Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Alkermes Inc
483
•Alkermes Inc•October 19, 2023

Alkermes Inc – FDA 483, Oct 19, 2023

Record Details

This FDA Form 483 was issued to Alkermes Inc., a manufacturer located in Wilmington, OH, following an inspection from September 25 to October 19, 2023. The inspection revealed seven observations regarding the firm's manufacturing and quality control processes.

Observation 1 notes inadequate validation of sterile drug product processes, specifically in smoke studies where unidirectional airflow was not demonstrated due to improper probe positioning and camera angles.

Observation 2 highlights deficiencies in laboratory controls, including the lack of inspection and documentation for sterile gloves upon receipt, and the absence of appropriate procedures to qualify microbiologists for counting Colony Forming Units (CFU) on media plates.

Observation 3 indicates insufficient controls over computer systems, as audit trails or revision histories of the (b)(4) system used for drug product analysis are not reviewed by the quality unit to detect unauthorized changes.

Observation 4 details inadequate employee training. Supervising microbiologists overseeing environmental and personal monitoring, and water samples, lacked documented qualification for CFU counting. Additionally, the training procedure for microbial growth determination was deficient, lacking specifics on challenging CFU adequacy, counting methods, and visual aids.

Observation 5 states that the quality control unit's responsibilities and procedures are not fully followed. The change control procedure lacks predetermined criteria for post-implementation evaluation, and the firm failed to conduct or document effectiveness checks for ten reviewed change controls.

Observation 6 identifies an inadequate investigation into a quality-related complaint (PR

Company
Alkermes Inc
Inspection date
October 19, 2023
Product type
Drugs
Office
Cincinnati District Office
Person
  • Ucheabuchi C. Chudi-Nwankwor
View Company Profile

ID · 95258bb8-236c-40b0-8ccb-1570c9ec1064

Violation Codes1
21 U.S.C. 374(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Alkermes Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.